Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06997185 · ClinicalTrials.gov registry record · NA
Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
A NA study of Cancer, sponsored by London School of Economics and Political Science.
- Recruiting
- Registry status
- NA
- Development phase
- 3,000
- Enrollment target
- 1
- Study location
NCT06997185: Recruiting NA study of Cancer, sponsored by London School of Economics and Political Science.
NCT06997185 is a NA study of Cancer that is actively recruiting participants, run by London School of Economics and Political Science. The registered enrollment target is 3,000 participants, below the 3,486-participant average among 615 other Cancer trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06997185, a NA study of Cancer, is actively recruiting participants, sponsored by London School of Economics and Political Science.
- RECRUITING
- Registry status
- NA
- Development phase
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate different sources of uncertainty about the benefits and harms of new cancer drugs on participants' decisions and understanding.
Primary Outcome
"Imagine you were Alex and diagnosed with non-small cell lung cancer. How likely are you to take the new drug, Zenova?" 4-point Likert scale for decision: very likely; somewhat likely; somewhat unlikely; very unlikely.
Conditions Studied
Interventions
- OTHER Statement communicating uncertainty with a single arm trial
- OTHER Statement communicating uncertainty with limited study duration
- OTHER Statement communicating uncertainty with a limited study population
- OTHER Statement communicating uncertainty with an unvalidated surrogate endpoint
- OTHER Statement communicating uncertainty with treatment effect size
Study Locations (1)
Massachusetts
- Harvard Medical School and Harvard Pilgrim Health Care Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2025-05-09 |
| Est. Completion | 2025-06 |
| Phase | NA |
What NCT06997185 shows while recruiting
NCT06997185 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,486-participant average among 615 other Cancer trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Statement communicating uncertainty with a single arm trial is the first listed.
NCT06997185 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06997185 about?
NCT06997185 is a clinical study titled "Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs". This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate different sources of uncertainty about the benefits and harms of new cancer drugs on participants' decisions and understanding.
What is the current status of trial NCT06997185?
This trial is currently recruiting. It is a NA study. The enrollment target is 3,000 participants. The study started on 2025-05-09. Estimated completion is 2025-06.
What conditions does trial NCT06997185 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT06997185?
The interventions under investigation include: Statement communicating uncertainty with a single arm trial (OTHER), Statement communicating uncertainty with limited study duration (OTHER), Statement communicating uncertainty with a limited study population (OTHER), Statement communicating uncertainty with an unvalidated surrogate endpoint (OTHER), Statement communicating uncertainty with treatment effect size (OTHER).
Who is sponsoring clinical trial NCT06997185?
This trial is sponsored by London School of Economics and Political Science, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06997185 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06997185's enrollment target sits among peer trials
3,000 50th of 615 higher than 565 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI